Exhibit 99.1 Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Recent Operational and Strategic Highlights: Financial Results • ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40288 Design Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-3929248 (State or other jurisdicti ...

Exhibit 99.1 Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif. – March 9, 2026 – Septerna, Inc. (Nasdaq: SEPN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Vail Resorts, Inc. (Exact Name of Registrant as Specified in Its Charter) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-09614 (State or Other Jurisdiction of Incorporation or Organizati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _________ to _________ Commission file number: 0-25923 Eagle Bancorp, Inc. (Exact name of registrant as specified in its charter) Maryland 52-2061461 (State or other jurisdictio ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 (Address of principal executive offices) (ZIP Code) Registrant's telephone number, including area code: (585) 786-1100 Securities registered under Section 12(b) of the Exchange Act: OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Exhibit 99.1 Vail Resorts Contacts: Investor Relations: Connie Wang, InvestorRelations@vailresorts.com Media: Sara Olson, News@vailresorts.com Vail Resorts Reports Second Quarter Fiscal 2026 Results and Provides Updated Fiscal 2026 Guidance BROOMFIELD, Colo. - March 9, 2026 - Vail Resorts, Inc. (NYSE: MTN) today reported results for the second quarter of fiscal 2026 ended January 31, 2026 and provided the Company's ski season-to-date metrics through March 1, 2026. Highlights Commenting on the Company's fisc ...

Exhibit 10.1 Zevra Therapeutics, inc. Employment Agreement Justin Renz Effective as of March 9 2026 Zevra Therapeutics, Inc. Employment Agreement The Employment Agreement ("Agreement" is made and entered into effective as of March 9, 2026 by and between Zevra Therapeutics, Inc., a Delaware corporation (the "Company"), including its affiliates, parent, subsidiaries, successors, and assigns Justin Renz("Executive") (each being "Party" hereto and together constituting the "Parties"). Whereas, the Company desir ...

Exhibit 10.1 Zevra Therapeutics, inc. Employment Agreement Justin Renz Effective as of March 9 2026 Zevra Therapeutics, Inc. Employment Agreement The Employment Agreement ("Agreement" is made and entered into effective as of March 9, 2026 by and between Zevra Therapeutics, Inc., a Delaware corporation (the "Company"), including its affiliates, parent, subsidiaries, successors, and assigns Justin Renz("Executive") (each being "Party" hereto and together constituting the "Parties"). Whereas, the Company desir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Registrant's telephone number, including area code) Commission File Number 001-36805 Box, Inc. (Exact name of registrant as specified in its Charter) Delaware 20-2714444 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2026 OR ☐ TRANSITION RE ...